Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Mosillo C, Iacovelli R, Ciccarese C, et al. De novo metastatic castration sensitive prostate cancer: state of art and future perspectives. Cancer Treat Rev. 2018;70:67–74. doi: 10.1016/j.ctrv.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Siegel DA, O'Neil ME, Richards TB, et al. Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473–1480. doi: 10.15585/mmwr.mm6941a1.
   PubMed Web of Science ®Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. doi: 10.1371/journal.pone.0139440.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Hormone Therapy for Prostate Cancer; 2021. Available from: https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html.
   Google Scholar
• Pagliuca M, Buonerba C, Fizazi K, et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs. 2019;79(4):381–400. doi: 10.1007/s40265-019-1060-5.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–5511. doi: 10.1038/onc.2013.206.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Adminsitration. FDA approves apalutamide for metastatic castration-sensitive prostate cancer 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer.
   Google Scholar
• U.S. Food and Drug Adminsitration. FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer 2018. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive.
   Google Scholar
• U.S. Food and Drug Adminsitration. FDA approves enzalutamide for metastatic castration-sensitive prostate cancer 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer.
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Andriole G, Freedland SJ, et al. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020;27(5):10352–10362.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Ke X, Lafeuille MH, et al. Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. J Urol. 2021;206(6):1420–1429. doi: 10.1097/JU.0000000000002121.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Sandin R, Sah J, et al. Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US veterans health administration. Cancer Med. 2021;10(23):8570–8580. doi: 10.1002/cam4.4372.
   PubMed Web of Science ®Google Scholar
• Devasia TP, Mariotto AB, Nyame YA, et al. Estimating the number of men living with metastatic prostate cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2023;32(5):659–665. doi: 10.1158/1055-9965.EPI-22-1038.
   PubMed Web of Science ®Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. medRxiv. 2020. doi: 10.1101/2020.03.16.20037143.
   Google Scholar
• Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv:200109765. 2020 doi: 10.48550/arXiv.2001.09765.
   Google Scholar
• Komodo Health Solutions. Imputing allowed amounts development and validation of an encounter-level allowed amount imputation model 2023. Available from: https://www.komodohealth.com/hubfs/2023/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf.
   Google Scholar
• Datavant. Overview of Datavant’s de-identification and linking technology for structured data 2020. Available from: https://datavant.com/wp-content/uploads/2021/08/White-Paper_-De-Identifying-and-Linking-Structured-Data_updated-3-10-2020.pdf.
   Google Scholar
• US Department of Health and Human Services. 45 CFR 46: pre-2018 requirements 2021 June 23, 2023. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.101.
   Google Scholar
• Ke X, Lafeuille M-H, Romdhani H, et al. Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US). J Clin Oncol. 2020;38(15_suppl):e19138–e19138. doi: 10.1200/JCO.2020.38.15_suppl.e19138.
   Google Scholar
• Ellinger J, Alajati A, Kubatka P, et al. Prostate cancer treatment costs increase more rapidly than for any other cancer-how to reverse the trend? EPMA J. 2022;13(1):1–7. doi: 10.1007/s13167-022-00276-3.
   PubMed Web of Science ®Google Scholar
• Olsen TA, Filson CP, Richards TB, et al. The cost of metastatic prostate cancer in the United States. Urol Pract. 2023;10(1):41–47. doi: 10.1097/UPJ.0000000000000363.
   PubMed Web of Science ®Google Scholar
• Reddy SR, Broder MS, Chang E, et al. Cost of cancer management by stage at diagnosis among medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285–1294. doi: 10.1080/03007995.2022.2047536.
   PubMed Web of Science ®Google Scholar
• Trinh QD, Chaves LP, Feng Q, et al. The cost impact of disease progression to metastatic castration-sensitive prostate cancer. J Manag Care Spec Pharm. 2022;28(5):544–554. doi: 10.18553/jmcp.2022.28.5.544.
   PubMed Web of Science ®Google Scholar
• Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–1090. doi: 10.1097/JU.0000000000003452.
   PubMed Web of Science ®Google Scholar
• Crigna AT, Samec M, Koklesova L, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? Epma J. 2020;11(4):603–627. doi: 10.1007/s13167-020-00226-x.
   PubMed Web of Science ®Google Scholar
• Kucera R, Pecen L, Topolcan O, et al. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. Epma J. 2020;11(3):399–418. doi: 10.1007/s13167-020-00214-1.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi: 10.1056/NEJMoa1702900.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi: 10.1056/NEJMoa1704174.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24. doi: 10.1056/NEJMoa1903307.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–1622. doi: 10.1200/JCO.22.00193.
   PubMed Web of Science ®Google Scholar
• Wenzel M, Preisser F, Hoeh B, et al. Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies. Front Oncol. 2021;11:659135. doi: 10.3389/fonc.2021.659135.
   PubMed Web of Science ®Google Scholar
• Graham LS, Lin JK, Lage DE, et al. Management of prostate cancer in older adults. Am Soc Clin Oncol Educ Book. 2023;43:e390396. doi: 10.1200/EDBK_390396.
   PubMedGoogle Scholar
• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0.
   PubMed Web of Science ®Google Scholar
• Wu B, Li SS, Song J, et al. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. J Med Econ. 2020;23(1):54–63. doi: 10.1080/13696998.2019.1678171.
   PubMed Web of Science ®Google Scholar
• Dovey Z, Mohamed N, Gharib Y, et al. Impact of COVID-19 on prostate cancer management: guidelines for urologists. Eur Urol Open Sci. 2020;20:1–11. doi: 10.1016/j.euros.2020.05.005.
   PubMedGoogle Scholar